Interested in molecular insights for tackling cancer therapy challenges? This review synthesizes recent research and translational directions.
Key Takeaways
- Acetyltransferase is the sole known writer of RNA ac4C modification
- It promotes therapy resistance via enhanced DNA repair, metabolic rewiring, and immune suppression
- Specific inhibitors Remodelin and repurposed fludarabine show preclinical translational potential